Cubist Pharmaceuticals Company Profile (NASDAQ:CBST)

Analyst Ratings

Consensus Ratings for Cubist Pharmaceuticals (NASDAQ:CBST) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cubist Pharmaceuticals (NASDAQ:CBST)
Show:
DateFirmActionRatingPrice TargetActions
12/22/2014Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014GabelliDowngradeBuy -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$84.00 -> $102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014MizuhoDowngradeBuy -> Neutral$97.00 -> $102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014Jefferies GroupDowngradeBuy -> Hold$88.00 -> $102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014SunTrust Banks Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014WedbushInitiated CoverageNeutral$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Cubist Pharmaceuticals (NASDAQ:CBST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/21/2014Q314$0.04$0.58$305.50 million$309.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/22/2014Q214$0.01$0.23$299.60 million$294.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$0.33$0.30$285.24 million$261.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/22/2014Q413($0.01)$0.29$285.47 million$299.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/17/2013Q313$0.34$0.41$267.96 million$266.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/18/2013Q2 2013$0.55$0.42$254.93 million$258.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/18/2013Q1 2013$0.50$0.34$243.55 million$229.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/23/2013Q4 2012$0.48$0.51$246.42 million$245.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/18/2012$0.47$0.55ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/19/2012$0.45$0.68ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/18/2012$0.63$0.82ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/19/2012$0.31$0.11ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/19/2011$0.26$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/14/2011$0.43($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2011$0.26$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/20/2011$0.34$0.24ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cubist Pharmaceuticals (NASDAQ:CBST)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cubist Pharmaceuticals (NASDAQ:CBST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/1/2014Steven C GilmanEVPSell48,125$65.39$3,146,893.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Gregory SteaSVPSell38,326$65.88$2,524,916.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Nancy J HutsonDirectorSell9,000$65.00$585,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Robert J PerezCOOSell1,003$63.68$63,871.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Steven C GilmanEVPSell40,625$61.57$2,501,281.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Michael BonneyCEOSell3,036$67.50$204,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Robert PerezCOOSell1,518$67.50$102,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Steven GilmanEVPSell16,340$67.82$1,108,178.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Michael BonneyCEOSell3,840$69.00$264,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Robert PerezCOOSell2,400$69.00$165,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Steven GilmanEVPSell1,680$69.00$115,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Gregory SteaSVPSell19,889$79.74$1,585,948.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Mark CorriganDirectorSell5,000$80.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Michael BonneyCEOSell100,000$81.25$8,125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Robert PerezCOOSell30,000$80.18$2,405,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Michael BonneyCEOSell3,112$75.60$235,267.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Kenneth BateDirectorSell6,250$72.15$450,937.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Gregory SteaSVPSell5,312$74.90$397,868.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Robert PerezCOOSell10,000$74.95$749,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Robert PerezCOOSell10,000$72.95$729,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Kenneth BateDirectorSell10,000$70.00$700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Steven GilmanEVPSell25,000$67.82$1,695,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Kenneth BateDirectorSell12,500$67.63$845,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Martin RosenbergDirectorSell15,472$65.00$1,005,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Robert PerezCOOSell1,024$60.55$62,003.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2013Gregory SteaSVPSell33,750$61.29$2,068,537.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Nancy J HutsonDirectorSell5,000$53.87$269,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/19/2013Gregory SteaSVPSell4,375$55.00$240,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Kenneth BateDirectorSell2,500$54.95$137,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Steven C GilmanEVPSell15,125$54.49$824,161.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Mark CorriganDirectorSell14,000$54.60$764,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013J Matthew SingletonDirectorSell27,500$55.48$1,525,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Charles Anthony LaranjeiraSVPSell14,000$51.43$720,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Michael W BonneyCEOSell60,000$50.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Robert J PerezCOOSell15,000$49.98$749,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Michael W BonneyCEOSell2,400$47.88$114,912.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Robert J PerezCOOSell1,500$47.88$71,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Steven C GilmanEVPSell1,201$48.88$58,704.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Kenneth BateDirectorSell2,500$48.41$121,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Michael W BonneyCEOSell2,979$48.41$144,213.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Robert J PerezCOOSell1,490$48.41$72,130.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Steven C GilmanEVPSell1,017$48.41$49,232.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Michael W BonneyCEOSell3,753$49.18$184,572.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Robert J PerezCOOSell2,346$49.18$115,376.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Steven C GilmanEVPSell1,135$49.18$55,819.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cubist Pharmaceuticals (NASDAQ:CBST)
DateHeadline
05/10/16 06:50 PMEPIRUS Biopharma to Slash 40% of Workforce and Replaces CEO - PharmaLive (press release) (subscription) - EPIRUS Biopharma to Slash 40% of Workforce and Replaces CEOPharmaLive (press release) (subscription)A managing partner at 5AM Ventures, Rocklage was also the founding chief executive officer of Cubist Pharmaceuticals (CBST), which sold to Merck & Co. (MRK) in 2015. Michael Wyand, the chief technology officer at Epirus, has been promoted to president ...and more »
04/09/15 03:06 PMSuperbugs Turn Big Pharma, Gov't Focus To Antibiotics -
03/31/15 02:50 AMMario Gabelli's Top 5 Stock Picks -
03/20/15 03:06 PMFarallon Capital Starts New Position in Cubist Pharmaceuticals -
03/04/15 05:05 PMElliott Management exits position in Covidien -
03/02/15 05:05 PMElliott Management starts new position in Cubist Pharmaceuticals -
02/16/15 11:08 PMPrem Watsa's Stock Buys and Sells of Q4 -
01/20/15 04:45 PMDana Holding Set to Join the S&P MidCap 400 - [PR Newswire] - NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P ...
01/13/15 07:26 AMCubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights ...
12/19/14 05:07 PMFDA approves Cubists' drug for antibiotic-resistant bacteria -
12/10/14 07:50 AMCubist sales force seen as potential boon for Merck intestinal drug -
12/09/14 05:13 PMMerck says still plans to buy Cubist, despite patent setback -
12/09/14 09:27 AMMerck committed to Cubist after patent losses -
12/09/14 07:59 AMMerck says still plans Cubist purchase, despite patent setback -
12/09/14 07:50 AMAfter Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? -
12/08/14 05:39 PMMerck to take on superbugs with Cubist Pharma buy -
12/08/14 05:30 PMMerck dives into 'superbug' chase with Cubist -
12/08/14 05:09 PMMerck to buy Cubist Pharmaceuticals for $8.4 billion -
12/08/14 04:39 PMCourt rules Hospira can launch generic Cubicin in 2016 -
12/08/14 12:46 PMUS STOCKS-Wall St falls with energy shares; global data disappoints -
12/08/14 11:54 AMCubist options unusually active before Merck deal -
12/08/14 10:13 AMUS STOCKS-Wall St flat after Japan, China data; biotechs climb -
12/08/14 08:54 AMUS STOCKS-Wall St slips after Japan, China data; energy drags -
12/08/14 08:10 AMUS STOCKS-Wall St to open lower after Japan, China data -
12/08/14 07:20 AMMerck, Cubist Agree to $9.5 Billion Acquisition -

Social

About Cubist Pharmaceuticals

Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CBST
  • CUSIP: 22967810
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $85
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $1.14 EPS
  • Next Year EPS Consensus Estimate: $1.94 EPS
Additional Links:
Cubist Pharmaceuticals (NASDAQ:CBST) Chart for Monday, July, 25, 2016